Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna Inc  (NASDAQ:MRNA) stock was last seen up 15.4% to trade at $90.72, one of the best stocks on the Nasdaq today, after data from a mid-stage trial showed the company's experimental cancer vaccine with Merck (MRK), combined with immunotherapy Keytruda, helped melanoma patients reduce the risk of death or relapse after three years.

Moderna Stock on Track for Best Day Since 2022

Moderna Inc (NASDAQ: MRNA) is up nearly 15% this morning after reporting mid-stage trial data for its experimental vaccine for skin cancer.

Moderna stock popped 15% on Thursday: explore why

Adobe

Stocks continued to move higher following the Federal Reserve's latest decision. Adobe shares fell as strong financial results weren't enough to overcome worries about future growth.

2 Big Stocks Making Big Moves Thursday

Moderna (NASDAQ: MRNA ) stock is rising thanks to positive results from the skin cancer vaccine developed alongside Merck (NYSE: MRK ). The big news here comes after a Phase 2b trial of mRNA-4157 as an investigational individualized neoantigen therapy while combined with KEYTRUDA.

Why Is Moderna (MRNA) Stock Up 11% Today?

Carisma Therapeutics Inc

First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility, tolerability and early efficacy of in vivo CAR-M therapy utilizing mRNA/LNPs in solid tumors PHILADELPHIA , Dec. 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need.

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

Merck

Moderna Inc.'s stock MRNA, +0.72% soared 7% early Thursday, after the biotech and partner Merck MRK, +2.65% announced positive data from a mid-stage trial of Moderna's mRNA-4157 in combination with Merck's blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV). The companies said after about three years, the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62%, compared with Keytrua alone.

Moderna's stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck's Keytruda

An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time.

Benefits of Moderna and Merck melanoma vaccine plus Keytruda extend to three years

Moderna's Merck-partnered cancer vaccine reduced the risk of relapse or death by 49% in melanoma patients. Moderna stock could jump.

Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%; Will Shares Jump?

At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077) compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Data builds on the primary analysis reported at AACR and ASCO in 2023, which showed that mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% and reduced the risk of distant metastasis or death by 65% at a median planned follow-up of approximately two years Companies have initiated Phase 3 studies in the adjuvant setting in patients with high-risk melanoma and non-small cell lung cancer and plan to rapidly expand to additional tumor types CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / December 14, 2023/ Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV) following complete resection. In this planned analysis occurring with a median follow-up of approximately three years, adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful improvement in recurrence-free survival (RFS), reducing the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) compared with KEYTRUDA alone.

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp

Moderna's personalized cancer vaccine is being used with a Merck immunotherapy drug to fight melanoma cancer.

Moderna Reports More Promising Data on Its Cancer Treatment

Ginkgo Bioworks Holdings

Etsy

Stocks won't automatically become more expensive when we shift into a new year. But those that have struggled this year and have strong long-term outlooks could rebound at any point.

3 Dirt-Cheap Stocks to Buy Hand Over Fist Before the End of the Year

The second late-stage study will evaluate Moderna (MRNA)/Merck's investigational cancer combination therapy in certain lung cancer patients. A late-stage study in melanoma indication is ongoing.

Moderna (MRNA), Merck Start 2nd Late-Study on Cancer Therapy

U.S. drugmaker Moderna said on Tuesday Chief Commercial Officer (CCO) Arpa Garay has stepped down more than a year after she took on the role.

Moderna chief commercial officer steps down

Moderna Inc. MRNA, +2.09% on Tuesday announced a reorganization designed to sharpen the company's focus on driving sales of COVID vaccine Spikevax and on the expected 2024 launch of a vaccine for respiratory syncytial virus. Stephane Bancel, Moderna's CEO, will take on responsibility for sales and marketing next year, the company said, working directly with the commercial team.

Moderna reorganizes to sharpen focus on vaccine sales, chief commercial officer to leave company

CAMBRIDGE, MA / ACCESSWIRE / December 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals. The Company is focused on driving continued sales of its COVID-19 vaccine and launching its RSV vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward.

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025

APA Corporation

Bio-Rad Laboratories

Caesars Entertainment

First Solar

Halliburton

Las Vegas Sands

NVIDIA

Schlumberger

Wynn Resorts

Want to own the top S&P 500 stock of 2024? It's not going to be Nvidia again — and it won't even be in the top 10, analysts say.

Analysts Predict These Will Be Next Year's Top 10 Stocks

Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.

Moderna, Merck begin late-stage study for mRNA cancer therapy

Stock market all-stars impress us year after year with earnings growth and long-term share performance. You can get in on these players at any time during their story as a company -- but it's especially rewarding to invest early.

These 2 Stocks Are All-Stars in the Making

Moderna, Inc. (NASDAQ:MRNA ) 2023 ESG Day Conference Call December 7, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head of Investor Relations Stéphane Bancel - Chief Executive Officer Kyle Holen - Head of Development, Oncology & Therapeutics Jameka Hill - Senior Director, Clinical Trial Health Equity Hamilton Bennett - Senior Director of Vaccine Access & Partnerships Deborah Donovan - Senior Vice President and Head Environment, Health & Safety Tracey Franklin - Chief Human Resources Officer Katherine O'Malley - Executive Director of Communications Shannon Klinger - Chief Legal Officer Conference Call Participants Operator Good morning or good afternoon, everyone and welcome to Moderna's second ESG Day. Today, you will hear from team members across Moderna about progress we've made since last year, an important sustainability initiatives.

Moderna, Inc. (MRNA) 2023 ESG Day Conference (Transcript)

The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to employees and communities CAMBRIDGE, MA / ACCESSWIRE / December 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today will provide an update on its Environmental, Social and Governance (ESG) strategy at its second ESG Investor Event. Building off its inaugural ESG Day in November 2022, the Company will highlight the year's progress on its ESG journey and future work to further impact global health and protect the environment.

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event

Moderna Therapeutics Inc (NASDAQ:MRNA)'s upcoming update on its cancer vaccine trial in patients with adjuvant melanoma will only prompt a modest positive stock reaction, according to analysts at Jefferies. The drugmaker is expected to provide an update on the cancer vaccine (INT) trial at 51 events by the year-end, following its previous first interim update at 40 events.

Moderna cancer vaccine data expected to deliver only modest upside

Apple

Carnival

Carnival and Apple both have climbed this year -- but they still have plenty of room to run thanks to customer demand. Investors have shied away from Moderna as vaccine demand falls, but a new wave of growth may lie ahead thanks to potential new products.

3 Dirt Cheap Stocks You'll Regret Not Buying Before the New Year

Agiliti Inc

AdaptHealth Corp

Digital Turbine

Clearfield

Cytek Biosciences

3D Systems

Enphase Energy

Harmony Biosciences Holdings

Lumen Technologies

SunPower

Vir Biotechnology

According to a study published this summer in The Review of Financial Studies, these vulnerable stocks are the ones that are most difficult to borrow and then sell short.

Why these stocks could lose money even if the market gains

Moderna, Inc. (NASDAQ:MRNA ) 35th Annual Piper Sandler Healthcare Conference November 30, 2023 12:30 PM ET Company Participants Jamey Mock - CFO Conference Call Participants Ted Tenthoff - Piper Sandler Ted Tenthoff My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler.

Moderna, Inc. (MRNA) Presents at 35th Annual Piper Sandler Healthcare Conference (Transcript)

Novavax

Pfizer

The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.

News for Moderna Stock (MRNA)